The outcomes of T cell activation and differentiation studies suggest that FOXM1 plays a crucial role in the modulation of tumor immune response and the utilization of FOXM1i could be a promising combinatorial approach to enhance the efficacy of immune-checkpoint blockers both in naïve and CR SCLC patients and help to shape the SCLC immune microenvironment towards enhanced antitumor immune response. Here, FOXM1 is linked to small cell lung carcinoma.